Whole-Body MRI — Myeloma, Metastases & Screening

Whole-Body MRI

Imaging head-to-thighs in one sitting — without radiation — to find and track disease across the whole skeleton and beyond.

How it works

Whole-body MRI stitches together multiple stations, typically combining anatomical sequences with diffusion-weighted imaging (DWI). DWI highlights cellular disease against normal marrow, and inverted greyscale maps give a PET-like overview of active lesions — all without ionising radiation.

The lack of radiation makes WB-MRI attractive for repeated staging and for surveillance in young, high-risk patients.

Main uses

Multiple myeloma: now a recommended tool for staging and detecting focal lesions earlier than skeletal survey.
Metastatic bone disease: staging and treatment-response assessment, e.g. in prostate and breast cancer.
Cancer-predisposition surveillance: screening in syndromes such as Li-Fraumeni.
Selected screening: increasingly offered privately — with important caveats about incidental findings.

The screening caveat

As a general “wellness” screen in asymptomatic people, WB-MRI frequently finds incidentalomas — benign findings that trigger anxiety, further tests and procedures without clear survival benefit. Its evidence base is strongest in defined high-risk groups and specific cancers, not the worried well.

Reference: Messiou C et al. Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma (MY-RADS). Radiology 2019;291:5–13.

Educational summary for clinicians; screening use is debated and should follow evidence-based guidance. Not medical advice.